PRC Call for Research Proposals
Submission guidelines

The Polio Research Committee (PRC) is currently soliciting research proposals focusing on topics outlined on page 2. Proposals will be reviewed at the next PRC meeting, to be held in May 2010 in Geneva, Switzerland.

Researchers are invited to submit proposals by 30 March 2010 to the Research and Product Development team, Global Polio Eradication Initiative, WHO Geneva, at email polioresearch@who.int.

The standard research proposal form is available at www.polioeradication.org/content/fixed/opvcessation/opvc_researchproposals.asp

All research proposals should include the following information:

1. Research question/objectives (e.g., clarity of questions, reference to published literature and cutting-edge science, description of how the results will be utilized).
2. Qualification of investigators and collaborators (e.g., track record of researchers, capability of laboratory, necessary contractual arrangements).
3. Budget request (e.g., appropriate for work anticipated).
4. Study design and methodology (e.g., clarity of activities, availability of institutions, feasibility of methods, compliance with Good Clinical Practice guidelines, plans for ethical and regulatory approvals).

In conclusion, the PRC recommended that the GPEI focus its research especially on:

1) Research to understand both epidemiology and potential intervention to boost mucosal immunity in northern India; and,
2) Operational research to improve vaccine coverage and immunity (both in polio-endemic and re-infected countries).

Please see page 2 for more detailed description of research priorities.

Conclusions and Recommendations of Polio Research Committee

The Polio Research Committee (PRC) provides guidance on overall strategic direction in research, identifies unmet research needs, and assists in identifying investigators and designing studies to answer unanswered research questions.

The 4th meeting of the PRC was convened in Geneva, Switzerland in November 2009, to provide the Global Polio Eradication Initiative (GPEI) with expert advice on:

- reasons for ongoing wild poliovirus circulation in India (specifically is vaccine efficacy a continuing problem);
- innovative ways to improve immunization coverage in Nigeria

evaluate more creative ways of reaching children and the value of the Polio Research Committee (PRC) to this work.

At the November 2009 meeting of the PRC, discussion centred on research to close operational gaps in settings such as northern Nigeria as well as boost mucosal immunity in settings such as northern India.

This issue of the Polio Pipeline will examine the outcomes of those discussions and outline new research to maximize the benefits of polio eradication strategies.

Polio research: helping reach more children and enhancing both the humoral and mucosal immunity

In 2009, major elements of the Global Polio Eradication Initiative (GPEI) Programme of Work included the evaluation of new tactical approaches in each polio endemic area, clinical trials of novel oral polio vaccine (OPV) formulations (bivalent OPV containing type 1 and type 3 serotypes), and a major Independent Evaluation of Major Barriers to Interrupting Poliovirus Transmission.

The Independent Evaluation validated the overall strategies for polio eradication, underscoring the importance of the programmatic decision to explore and

The Polio Pipeline: to subscribe to this quarterly newsletter, please email: polioresearch@who.int.
**RESEARCH AREA 1: UNDERSTANDING MUCOSAL IMMUNITY IN INDIA**

**Background**

The recent IPV/OPV study and surgeo survey in Moradabad, India, indicated the high per-dose efficacy for monovalent OPV type 1 (mOPV1) is higher (~60%) than previous estimates. These new data seem to increase importance of understanding vaccine-induced mucosal immunity in addition to humoral immunity in northern India.

The Polio Research Committee (PRC) recommend to:

a) investigate epidemiology and risk factors of decreased mucosal immunity;
b) evaluate possible intervention to boost mucosal immunity; and,
c) develop surrogate measurement of mucosal immunity against poliovirus.

**Examples of proposals to be considered include:**

a) Epidemiology and risk factors
   - Understand the rate of excretion among children (both below and over 5 years old) in high-risk area (or population) in Uttar Pradesh and Bihar.
   - Analyze AFP surveillance data to understand mucosal immunity induced by OPV (eg duration and extent of shedding, workup of contacts, full workup of a selected group for interactions between Sabin and other enteroviruses).
   - Investigate risk factors contributing to the decreased mucosal immunity (or continued excretion) among children under and over 5 years old.
   - Evaluate relationship between seroconversion and humoral or secretory antibody titer and excretion.
   - Evaluate the correlation between waning mucosal immunity among population and circulation of virus.

b) Intervention to help induce and maintain mucosal immunity
   - Evaluation of alternative formulation or simultaneous stimulation (OPV and IPV) to induce longer-lasting mucosal immunity.
   - Evaluation of other intervention (eg nutrition or parasite treatment).

c) Surrogate measurement of gut mucosal immunity
   - Validation of new methods or markers to measure gut immunity against poliovirus (including oral crevicular fluid sIgA, IgG).

**Not considered for funding:**

- Understand poliovirus circulation in low season.
- Surrogate measurement not related to gut mucosal immunity (eg oral, nasal).
- Testing interventions without a clear hypothesis of the link between intervention and mucosal immune function.
- Interventions and diagnostics which cannot be applied to the field settings.

---

**RESEARCH AREA 2: OPERATIONAL RESEARCH TO IMPROVE VACCINATION COVERAGE AND IMMUNITY**

**Background**

In some polio-endemic and re-infected countries, here is still room for further improvement in vaccine coverage and/or population immunity.

Communication research suggests that there are still gaps in knowledge, attitude and perception among caregivers and vaccinators in many countries.

The Polio Research Committee (PRC) recommend to:

a) evaluate new approaches to further increase vaccination coverage and population immunity;
b) develop and evaluate tools to improve SIA and AFP surveillance management; and,
c) evaluate vaccinator performance and assess ways to improve performance.

**Examples of proposals to be considered include:**

a) Evaluate new approaches to further increase vaccination coverage and population immunity
   - Test different communication and social mobilization strategies and evaluate their impact on acceptance and coverage.
   - Develop and test an innovative and simpler way to monitor immunization coverage (eg Lot Quality Assurance Sampling, use of IT to improve monitoring and activities).
   - Test feasibility and effectiveness of new approaches to increase the population immunity (eg zinc supplementation during SIAs, combination of OPV and IPV).

b) Develop and evaluate tools to improve SIA/AFP surveillance management
   - Develop and test management tools for assessing and optimising staff performance (eg proportion of staff time spent on identified priority/high-impact tasks).
   - Apply operational improvement methods proven in private sector (eg TQC*, Six Sigma**) to IPD/AFP surveillance operation.
   - Conduct external assessment of low-SIA performing areas (eg assess operational, attitudinal and organizational issues).

c) Evaluate vaccinator performance and assess ways to improve performance
   - Identify best practices with focus on optimising vaccinator selection, training, supervision and incentive/remuneration.

**Not considered for funding:**

- Test interventions which is not proven anywhere else.
- Evaluate activities without clear study question and/or hypothesis.

---

* Total quality control (TQC) is management philosophy to apply quality management principles to all areas of business from design to delivery
** Six Sigma is management strategy which seeks to improve the quality of process outputs by identifying and removing the causes of defects (errors) and minimizing variability in manufacturing and business processes
Delivering monovalent OPV to children in hard-to-reach communities using the Short Interval Additional Dose (SIAD) approach

The rationale for supplementary immunization activities (SIAs) is to rapidly increase population immunity by reaching a target population within a short period of time with oral polio vaccine (OPV). Historically, subsequent trivalent OPV doses had to be administered with an interval of four to six weeks, due to the known persistence of vaccine-virus in a child’s gut for up to six weeks, risking interference between the three different types of poliovirus contained in trivalent OPV. Since the licensure and use of monovalent OPVs in mid-2005, the issue of interference in subsequent dose administration has been removed, as only one poliovirus strain is contained in such vaccines. This new tool has enabled the implementation of a new approach - the Short Interval Additional Dose (SIAD) strategy. The SIAD approach enables a more rapid raising of population immunity levels, by administering two doses of monovalent OPV over the course of one to two weeks (as opposed to four to six weeks). This approach has proved particularly valuable in areas where populations may be difficult to reach, such as in conflict-affected areas or among nomadic populations, and may play a significant role in new outbreak settings. By rapidly administering two doses during a window of opportunity (such as a temporary cessation of conflict), children who would otherwise not have benefited from two doses are now able to be more rapidly protected against specific serotypes of the disease.

Following its successful application in Somalia which helped the country become again polio-free in March 2007, the SIAD approach has since established itself as a core eradication strategy between large-scale National and Subnational Immunization Days (NIDs and SNIDs) in areas of Pakistan and Afghanistan, as well as in outbreak settings (eg Kenya).

Research to validate SIAD

While the programmatic imperative for using monovalent OPVs during SIAD campaigns is persuasive, the scientific basis for SIAD is not fully established. The only data are from industrialized countries from the late 1950s and early 1960s where monovalent OPV was administered in shorter intervals under study conditions. However, these studies had very small sample sizes and cannot be easily projected onto developing country settings.

To correct this gap, and to establish a better scientific basis for SIAD, the Polio Research Committee (PRC) has approved funding for a clinical trial in Egypt that will assess SIAD rounds in young infants. The three arms of the trial include two intervention arms (that will administer monovalent OPV type 1 with intervals of seven days or 14 days) and a control arm that will provide monovalent OPV type 1 with an interval of 30 days. The study protocol is currently being reviewed by the respective ethical review committees at the World Health Organization and in three collaborating institutions in Egypt. The trial is due to start in the first quarter of 2010, and the results should be available in the third quarter.

Independent Evaluation calls for more research to maximize impact of eradication strategies

In 2009, an Independent Evaluation of Major Barriers to Interrupting Poliovirus Transmission was conducted, in response to a request in January 2009 from the Executive Board of the World Health Assembly, prompted by delays in attaining global eradication.

The Independent Evaluation comprised five sub-teams with a total of 28 experts in relevant disciplines, including public health, immunization, vaccinology, social mobilization and security. These sub-teams worked in Afghanistan, Angola, India, Nigeria, Pakistan, Sudan and the WHO Regional offices for Africa and the Eastern Mediterranean, in consultation with partners and stakeholders in each country.

While the Independent Evaluation provided a range of new technical recommendations for each polio-affected area, such as the rapid application of new tools including bivalent OPV, the group’s recommendations also have significant implications for the Global Polio Eradication Initiative’s research programme.

In particular, the group reinforced the importance of an aggressive and multi-pronged research agenda to overcome the unique challenge posed by incomplete gut mucosal immunity to polioviruses and uniquely efficient virus transmission in the setting of northern India. To this effect, conferred gut immunity by oral polio vaccine (OPV) versus inactivated polio vaccine (IPV) should be evaluated, as well as the effect of poor nutrition and chronic diarrhoeal incidence on immunity levels. At the same time, the effects of adding zinc supplementation (which has been shown to be associated with a reduction in diarrhoeal incidence) during polio supplementary immunization activities, and the benefits of implementing basic sanitation measures (eg protecting hand-pumps from faecal contamination), should be examined. For other areas, in particular in outbreak settings, the benefits of the new Short Interval Additional Dose (SIAD) approach should be quantifiably evidenced (see article on evaluating SIAD in outbreak settings above).

Global status of licensure and pre-qualification processes for monovalent OPV type 1, 2 and 3 and bivalent OPV

**Monovalent OPV type 1 (mOPV1)**

<table>
<thead>
<tr>
<th>Licensed in</th>
<th>mOPV1</th>
<th>mOPV1</th>
<th>mOPV1</th>
<th>mOPV1</th>
<th>mOPV1</th>
<th>mOPV1</th>
<th>mOPV1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panacea</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(Bio Farma &amp; Sanofi Pasteur bulks)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(Bio Farma bulks)</td>
<td>(Bio Farma bulks)</td>
</tr>
<tr>
<td>France</td>
<td>/</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Egypt</td>
<td>/</td>
<td></td>
<td>19 April 2005</td>
<td>7 February 2006</td>
<td>/</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belgium</td>
<td>/</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>18 July 2005</td>
<td>/</td>
</tr>
<tr>
<td>Italy</td>
<td>/</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>14 December 2007</td>
<td>/</td>
</tr>
<tr>
<td>Indonesia</td>
<td>June 2006 (SAS)*</td>
<td>/</td>
<td>2006 (SAS)*</td>
<td>/</td>
<td>20 February 2006</td>
<td>/</td>
<td></td>
</tr>
</tbody>
</table>

**Prequalification completed**

- 3 November 2009
- 8 May 2008
- 29 October 2009
- 3 November 2009
- 3 November 2009
- 3 November 2009
- Clinical trials ongoing in India

**Prequalification completed**

- 3 November 2009
- 8 May 2008
- 29 October 2009
- 3 November 2009
- 3 November 2009
- 3 November 2009
- Clinical trials ongoing in India

**Monovalent OPV type 3 (mOPV3)**

<table>
<thead>
<tr>
<th>Licensed in</th>
<th>mOPV3</th>
<th>mOPV3</th>
<th>mOPV3</th>
<th>mOPV3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panacea</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>India</td>
<td>10 August 2005</td>
<td>4 September 2008</td>
<td>4 September 2008</td>
<td>Ongoing</td>
</tr>
<tr>
<td></td>
<td>(Bio Farma &amp; Novartis bulks)</td>
<td></td>
<td></td>
<td>(Bio Farma bulks)</td>
</tr>
<tr>
<td>France</td>
<td>/</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Belgium</td>
<td>/</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Egypt</td>
<td>/</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pakistan</td>
<td>Ongoing</td>
<td>20 August 2007</td>
<td>6 June 2008</td>
<td>/</td>
</tr>
<tr>
<td>Nigeria</td>
<td>2 July 2007</td>
<td>31 October 2007</td>
<td>31 December 2008</td>
<td>/</td>
</tr>
<tr>
<td>Italy</td>
<td>/</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Indonesia</td>
<td>/</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Letter to UN</td>
<td>13 September 2005</td>
<td>21 March 2007</td>
<td>20 December 2007</td>
<td>/</td>
</tr>
</tbody>
</table>

**Prequalification status***

- Ongoing
- Ongoing
- Ongoing
- PSF review ongoing

**Prequalification completed**

- Q1 2010
- Q1 2010
- Q1 2010
- Clinical trials ongoing in India

**Bivalent OPV containing type 1 and 3 (bOPV1&3)**

<table>
<thead>
<tr>
<th>Licensed in</th>
<th>bOPV1&amp;3</th>
<th>bOPV1&amp;3</th>
<th>bOPV1&amp;3</th>
<th>bOPV1&amp;3</th>
<th>bOPV1&amp;3</th>
<th>bOPV1&amp;3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Panacea</td>
<td>License ongoing</td>
<td>License ongoing</td>
<td>License ongoing</td>
<td>License ongoing</td>
<td>License ongoing</td>
<td>License ongoing</td>
</tr>
<tr>
<td>India</td>
<td>25 November 2009</td>
<td>(Bio Farma bulks)</td>
<td>License ongoing</td>
<td>(Sanofi Pasteur bulks)</td>
<td>Ongoing</td>
<td>Ongoing</td>
</tr>
<tr>
<td>France</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Belgium</td>
<td>/</td>
<td>/</td>
<td>9 October 2009</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Egypt</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Pakistan</td>
<td>/</td>
<td>/</td>
<td>Ongoing</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Nigeria</td>
<td>/</td>
<td>/</td>
<td>Ongoing</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Italy</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Indonesia</td>
<td>/</td>
<td>/</td>
<td>Ongoing</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
<tr>
<td>Clinical trials status</td>
<td>Completed</td>
<td>Completed</td>
<td>Completed</td>
<td>Completed</td>
<td>Completed</td>
<td>Ongoing</td>
</tr>
</tbody>
</table>

**Prequalification status**

- 10 December 2009
- Ongoing
- 29 October 2009
- Ongoing
- Ongoing
- Ongoing

---

* SAS: special access scheme for specific use
** The letter sent to UNICEF recommends the procurement of the product
*** Completion of the prequalification process depends on satisfactory outcome of ongoing clinical trials
The use of LQAS to assess polio immunization coverage in Nigeria

Ensuring consistently reliable monitoring data of supplementary immunization activities (SIAs) is a key factor to ensuring polio eradication strategies are effectively implemented. A new tactic of the new Global Polio Eradication Initiative Programme of Work 2010-2012 will be to ensure enhanced monitoring of SIAs, both in endemic and outbreak areas.

To this effect, the World Health Organization has been adapting and testing the Lot Quality Assurance Sampling (LQAS) method, which classifies areas of interest (corresponding to “lots”) as having acceptable or unacceptable levels of vaccine coverage, to evaluate vaccination programmes in developing countries.

Conducting LQAS surveys in the field is straightforward: if in a sample of individuals the number of unvaccinated exceeds a pre-set decision value, then the area (lot) is classified as having an unsatisfactory level of vaccine coverage and mop-up activities are recommended.

This ease of application makes the LQAS a very operational tool to detect pockets of low vaccine coverage and therefore direct focused vaccination efforts.

In Nigeria, the Global Polio Eradication Initiative piloted a study to assess OPV coverage in 20 local government areas (LGAs) in five high-risk states using LQAS during the November 2009 Immunization Plus Days.

Two LGAs were accepted at target coverage of 90%, seven rejected with coverage below 90%, a further seven rejected with coverage below 70% and four rejected with coverage below 50%

The pilot proved that LQAS is feasible and useful for the polio eradication programme to efficiently monitor and guide future OPV campaigns in Nigeria and other polio-infected countries.

Where are the immunity gaps?

A number of studies looking at the immunity profile of infants and children in India have now been completed and preliminary results are available. These studies include: (1) re-testing of the 2007 seroprevalence survey in Mordadabad district in Uttar Pradesh state; (2) the 2009 Moradabad trial; and, (3) the seroprevalence survey among cases with acute flaccid paralysis (AFP) in western Uttar Pradesh.

The laboratory processing of these samples was conducted by the Enterovirus Research Centre in Mumbai, India and by the US Centers for Disease Control and Prevention (CDC) in Atlanta, USA. While the detailed analyses are pending finalization and the ensuing results will likely be published in the scientific literature in the course of 2010, there are a number of interesting and sometimes unexpected preliminary results that will influence programmatic action and the research agenda for 2010-2011. These include: (a) the 2009 Moradabad trial reporting >99% seroprevalence to poliovirus type 1 among 6-9 months old infants; (b) significant improvements in type 1 seroprevalence between the 2007 survey and the 2009 trial in infants aged 6-9 months (approximately 20% points) due to substantial increases in the number of seronegative infants seroconvert seven days after receipt of an IPV dose, suggesting that most of these infants had been primed, and respond with an anamnestic immune response.

In summary, the existing immunity gaps in northern India are now focused primarily for types 2 and 3. As noted above, these studies raise a number of important issues: it is apparent that more research is needed both to characterize these immune responses, especially for mucosal immunity, and to devise new means to measure mucosal immunity and institute new measures to boost mucosal immunity. To that end, a number of studies are being planned for implementation in India and Cuba in 2010.